Clinical Trial

First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1)

Study acronym: HL-Russia-1
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The HL-Russia-1 is a non-randomized, open-label, multicenter, phase III, 3-arm study. The primary objective is to assess efficacy, safety and progression-free survival (PFS) of different approaches (earle favorable, early unfavorable and advanced stages) to first line chemotherapy for classical Hodgkin Lymphoma (HL).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2020-11-16; most recent amendment 2024-09-25.
Trial Details
NCT Number NCT04638790
Lead Sponsor State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia
Conditions Hodgkin Lymphoma, Adult
Enrollment 300 participants
Start Date 2020-02-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-09-27